Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Jane M. Grant-Kels MD, FAAD Advisory Board

Ashish C. Bhatia MD, FAAD Associate Editor

See All Experts

featured

Published in Dermatology

Journal Scan / Research · June 19, 2024

Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Hidradenitis Suppurativa

The Lancet

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Additional Info

Article Citation

The Lancet

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Lancet 2024 Jun 08;403(10443)2504-2519, AB Kimball, GBE Jemec, CJ Sayed, JS Kirby, E Prens, JR Ingram, A Garg, AB Gottlieb, JC Szepietowski, FG Bechara, EJ Giamarellos-Bourboulis, H Fujita, R Rolleri, P Joshi, P Dokhe, E Muller, L Peterson, C Madden, M Bari, CC Zouboulis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Hidradenitis Suppurativa

Additional Info

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Further Reading

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

Clinical Features and Treatment Outcomes Among Patients With Primary Cutaneous B-Cell Lymphomas

Clinical Characteristics and Outcomes of DPP-4 Inhibitor–Associated Bullous Pemphigoid

Efficacy and Safety of Tofacitinib vs Azathioprine in Patients With Alopecia Areata and Its Variants

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for the Treatment of Patients With Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Association Between Treatment With Biologics and Cardiovascular Comorbidities in Patients With Psoriasis

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma, Atypical Spitz Tumors, and Non-Spitz Melanocytic Tumors

Recently Updated